InVitro International
IVRO · OTC
9/30/2025 | 9/30/2024 | 9/30/2023 | 9/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.75 | 0.00 | -9.44 | -0.88 |
| FCF Yield | -0.64% | 4.35% | -4.60% | 2.12% |
| EV / EBITDA | 7.56 | 19.54 | 148.17 | 14.61 |
| Quality | ||||
| ROIC | 4.42% | 3.58% | -1.12% | -13.71% |
| Gross Margin | 81.70% | 80.55% | 80.24% | 79.69% |
| Cash Conversion Ratio | -0.06 | 0.92 | -38.06 | 1.91 |
| Growth | ||||
| Revenue 3-Year CAGR | 3.51% | -1.68% | -7.56% | -8.24% |
| Free Cash Flow Growth | -108.80% | 264.44% | -291.88% | 8.16% |
| Safety | ||||
| Net Debt / EBITDA | -2.92 | -0.69 | -46.88 | -74.89 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.88 | 0.86 | 0.96 | 1.10 |
| Cash Conversion Cycle | 431.42 | 449.60 | 405.88 | 342.72 |